Cargando…
Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
BACKGROUND: Immune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare. CASE...
Autores principales: | Tan, Qiaoyun, Liu, Lichao, Huang, Yu, Dong, Xiaorong, Chen, Lingjuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732564/ https://www.ncbi.nlm.nih.gov/pubmed/36505877 http://dx.doi.org/10.3389/fonc.2022.973421 |
Ejemplares similares
-
Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report
por: Miranda Baleiras, Mafalda, et al.
Publicado: (2022) -
An autopsy case of autoimmune meningoencephalitis caused by pembrolizumab
por: Hiraoka, Yuhi, et al.
Publicado: (2022) -
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
por: Cafaro, Alessandro, et al.
Publicado: (2020) -
Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review
por: Marvin, Eric A., et al.
Publicado: (2020) -
Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)